HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not available. The isolation of broadly neutralizing antibodies (bnAbs) from HIV-infected patients has led to renewed hope for a prophylactic vaccine capable of combating the scourge of HIV. A major challenge is the design of immunogens and vaccination protocols that can elicit bnAbs that target regions of the virus’s spike proteins where the likelihood of mutational escape is low due to the high fitness cost of mutations. Related challenges include the choice of combinations of bnAbs for therapy. An accurate representation of viral fitness as a function of its protein sequences (a fitness landscape), with explicit accounting of the effects of c...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
Thesis: Ph. D., Harvard-MIT Program in Health Sciences and Technology, 2018.Cataloged from PDF versi...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
SummaryA prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic grip...
A prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic gripping su...
Viral immune evasion by sequence variation is a major hindrance to HIV-1 vaccine design. To address ...
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retr...
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retr...
AbstractBroadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) are cons...
SummaryA prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic grip...
Broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) are considered v...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
Thesis: Ph. D., Harvard-MIT Program in Health Sciences and Technology, 2018.Cataloged from PDF versi...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
HIV is a highly mutable virus, and over 30 years after its discovery, a vaccine or cure is still not...
SummaryA prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic grip...
A prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic gripping su...
Viral immune evasion by sequence variation is a major hindrance to HIV-1 vaccine design. To address ...
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retr...
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retr...
AbstractBroadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) are cons...
SummaryA prophylactic or therapeutic vaccine offers the best hope to curb the HIV-AIDS epidemic grip...
Broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) are considered v...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
Thesis: Ph. D., Harvard-MIT Program in Health Sciences and Technology, 2018.Cataloged from PDF versi...